trial

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

NCTId NCT03999190
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Withdrawn
Enrollment 0 (actual)
Sponsored by NYU Langone Health
Primary completion 2025-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2019-07
Primary completion
2025-07
Eligibility
FEMALE · 18 Years · 35 Years

Interventions & indications

Drugs
NPA radiotracerRaclopride radiotracerDextroamphetamine

Sponsors

NYU Langone HealthLead Sponsor

Investigators

1
William FranklePrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2025-07
Status
WITHDRAWN
relationships
The graph out of here
drug
NPA radiotracer
drug
Raclopride radiotracer
drug
Dextroamphetamine
drug
lead_sponsor
NYU Langone Health
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
William Frankle
person